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Background: To enable primary care medical practitioners to generate a range of possible service
delivery models for genetic counselling services and critically assess their suitability.
Methods: Modified nominal group technique using in primary care professional development
workshops.
Results: 37 general practitioners in Wales, United Kingdom too part in the nominal group process.
The practitioners who attended did not believe current systems were sufficient to meet anticipated
demand for genetic services. A wide range of different service models was proposed, although no
single option emerged as a clear preference. No argument was put forward for genetic assessment
and counselling being central to family practice, neither was there a voice for the view that the
family doctor should become skilled at advising patients about predictive genetic testing and be able
to counsel patients about the wider implications of genetic testing for patients and their family
members, even for areas such as common cancers. Nevertheless, all the preferred models put a
high priority on providing the service in the community, and often co-located in primary care, by
clinicians who had developed expertise.
Conclusion: There is a need for a wider debate about how healthcare systems address individual
concerns about genetic concerns and risk, especially given the increasing commercial marketing of
genetic tests.
Background
'Imagine what it would be like if doctors could look at
your medical future' says an advert in the Harvard Busi-
ness Review [1]. If companies are already marketing the
possibility of a genetic manipulated future, is it not time
doctors considered how to manage what will become a
growing area of work? Genetics will alter the face of med-
icine, as the inherited components of common diseases
and cancers are uncovered and patients' awareness of sus-
ceptibility increases. This trend is likely to lead to more
individuals approaching primary care for guidance, for
genetic risk assessment or counselling and perhaps testing
[2,3]. Many practitioners are confident that generalists can
absorb this demand by increasing their knowledge and
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making use of new software [4,5]. Others are sceptical and
fear primary care clinicians will not want the additional
task of providing genetic advice [6], adamant that this new
role – both in time and effort – goes beyond what can be
realistically provided. Patients are not concerned with
such debates: they look for convenient access to effective
services [7]. Should primary care respond to these
demands and if so, how? If not, are we guilty of allowing
technological developments in predictive testing and
commercial pressures overtake the ability of services to
react appropriately, leaving individuals with genetic con-
cerns unsupported? [8,9]
Genetics clinics are experiencing workload increases [10].
Referrals to cancer genetic services are a particular area of
demand as predictive genetic testing for breast, ovarian
and colorectal cancer becomes more widely known [10].
To meet this demand, genetic services are experimenting
with new methods of service delivery. A number of mod-
els are reported and include initiatives such as initial risk
assessments by mailed questionnaire or telephone inter-
view or the use of letters to transmit risk information to
referred patients without brining them to clinic [11,12].
Some services are examining the use of non-medical
genetic counsellors to assess family pedigrees and are
using nurses to undertake specialised genetic counselling.
Some services have explored the use of video-conferenc-
ing in order to increase access to populations that live in
rural areas [13]. Nevertheless, the basic service delivery
model is still one predicated on specialist care: general
practitioners refer patients to the secondary (or tertiary)
care sector. As yet, there has been no guideline that indi-
cates that some genetic issues should be managed in pri-
mary are, although guidelines are emerging that ask
generalists to stratify risk by categorising patients accord-
ing to risk and to only refer those above a suggested
threshold. However, as demand for genetic services con-
tinues to grow, the viability of this service delivery model
needs to be examined.
As elsewhere in the UK, genetic services in Wales are pro-
vided at a regional level, using a distributed clinic
approach in three centres (North, West and the South
East). Referrals are accepted from a range of sources, and
for cancer genetic referrals a triage system involving postal
questionnaire and telephone assessment is used to stratify
patients into low, medium and high-risk groups. Given
increasing demand however, there is speculation that
genetics could be integrated into community settings, per-
haps in family practice, close to kinship relationships and
in a context of continuous care. However, there are also
concerns about patients living 'at risk' with no obvious
means of support [10]. Genetic risk assessment is a task
requiring a detailed history, and where there are uncer-
tainties regarding neoplasm in other family members, val-
idation of disease by pathological confirmation is
necessary. To determine individual risk, family members
have to be contacted and blood samples obtained for
DNA analysis from living affected relatives. This process is
lengthy, complex and depends on effective communica-
tion between health care professionals, their patients,
family members and between health professionals them-
selves. Is it feasible that primary care services can be re-
designed to enable genetic risk assessment and counsel-
ling for those identified as moderate to high risk to take
place and then referred onwards to the appropriate spe-
cialist service?
This study aimed to enable general practitioners to gener-
ate possible delivery models for genetic services and then
critically assess these different possibilities over the next
five to ten years. To facilitate the emergence of a wide
range of options and possibilities a modified nominal
group technique was employed.
Methods
General practitioners were invited to discuss develop-
ments in genetics, emphasising cancer genetics, and to
consider how services could be re-designed to meet antic-
ipated growth in patient demand for genetic advice, coun-
selling and further management. To obtain a varied
sample, meetings were arranged in three different loca-
tions (Swansea, Newport and Cardiff). Two mailings were
circulated to all practitioners in the relevant catchment
areas using details available to the postgraduate offices.
Approximately 150 practitioners were mailed each area.
The meetings were described as having two broad aims:
firstly, to inform general practitioners about develop-
ments in genetics and how these might translate into
patient concerns. Secondly, to involve practitioners in
considering how genetic services could best meet this
anticipated increased demand. The meetings took place
between March and September 2003, at broadly the same
time as the implementation of the new contract for gen-
eral practice in the UK [14].
The structure of the meetings was standardised. A special-
ist in medical genetics (JG) provided an overview of recent
advances in genetics and advised participants of the devel-
opments in predictive testing and pharmacogenetics. The
predicted increasing demand for genetic advice was dis-
cussed. The presentation described the process of assess-
ing family history, verifying verbal reports of diseases in
other family members, assessing and communicating
genetic risk to patients.
After this presentation, a modified nominal group tech-
nique was used [15]. Participants were asked to write,
without conferring, a list of possible service deliveryBMC Family Practice 2005, 6:14 http://www.biomedcentral.com/1471-2296/6/14
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models that could be designed to provide genetic services
to patients. Participants were asked to think creatively
about news kinds of services and, for the purposes of the
exercise, to put aside concerns about funding or the future
of general practice. A facilitator then asked each partici-
pant to describe the models they proposed, one at a time,
and they were outlined on flip charts. At this stage, the
facilitator (GE) clarified and categorised the models, to
remove duplications and arrived at an agreed list of service
delivery designs. After this list had been agreed, partici-
pants were asked to conduct brief (10–20 minute) small
group discussions in order to discuss the advantages and
disadvantages of each model. Each practitioner then inde-
pendently ranked the agreed models and the results were
shared and discussed. In order to compare the results of
the meetings, rankings given to different service delivery
models were given inverse scores, and totals calculated to
determine overall rankings.
Results
Three events were held at which a nominal group process
was undertaken immediately after a short standardised
presentation about recent developments in genetics and
cancer genetics. A total of 37 practitioners participated:
they represent practitioners who were mostly in the mid-
careers and were from a range of practice sizes. Compared
to other similarly advertised events, attendance was
approximately 50% lower: details of the attendees are pro-
vided in Table 1.
Participants proposed lists of service models ranging from
patient self-referral to telephone-based services such as
NHS Direct, to maintaining existing arrangements where
general practitioners continue to act as gatekeepers to
other services. After clarifying the nature of each proposed
model, the list was summarised and distinctive service
delivery models were given a short descriptive names.
Small group discussions were conducted to examine their
Table 1: Details of general practitioner participants at three nominal group events
Meeting Area Number at meeting Gender, (Mean number of 
years in practice)
Mean Practice Size (Whole 
Time Equivalent Doctors)
South West Wales 13 9 male, 4 female (17). 5
South East Wales 9 5 male, 4 female (13). 2
Cardiff 15 6 Male, 6, female, 3 not specified, 
(14).
4.6
Table 2: Genetic service delivery models proposed and ranked
Service Models Meeting 1 Meeting 2 Meeting 3
Rank Score Rank Score Rank Score Score Total
Community based service provided by genetic counsellors, not managed by general 
practice, but could be located in practices or local community centres to provide local 
patient assessment and advice.
181836 22
Enhanced primary care: a service located within primary care, with specialists in 
genetic risk assessment, with support made possible by information technology and 
software applications.
273618 21
Special 'genetic' clinics: this model was suggested so that the privacy and discretion 
analogous to 'genitourinary clinics' was built in, and where self-referral is possible and 
anonymity and confidentiality respected.
364527 18
Traditional gatekeeper model: where general practitioners undertake an initial 
assessment, using standardised referral guidelines, and refer patients who are not 
categorised as 'low' risk.
452745 17
Direct access telephone service: a 'genetics direct' model where patients have 
their genetic pedigrees assessed by counsellors with assess to pedigree software tools.
545454 12
Drop in service for genetic assessment: e.g. similar to the Citizen Advice Bureau 
model.
63---- 3
Private service: patients with concerns are directed to commercial providers either 
in the UK or elsewhere.
72---- 2
Pharmacy led service: patients with concerns are directed to pharmacists, who 
could also undertake pharmacogenetic profile testing and offer lifestyle advice.
81---- 1BMC Family Practice 2005, 6:14 http://www.biomedcentral.com/1471-2296/6/14
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pros and cons. At this point, each individual practitioner
was asked to rank his or her preferred service models. The
hypothetical service delivery models, their ranking at each
meeting and overall ranking are provided in Table 2.
Table 2 illustrates the range of possible models generated
during the nominal groups and shows that general practi-
tioners are willing to consider a range of service delivery
methods. Compared to the other two meetings, practi-
tioners at the first meeting (south west Wales) generated
many innovative approaches, including a telephone-
based service integrated with an on-line family pedigree
software and a suggestion that community pharmacists
might wish to develop a role as genetic counsellors.
Another suggestion was a 'drop in' centre as an attempt to
'de-medicalise' the assessment of an individual's genetic
make-up. Some practitioners were aware of commercial
companies selling genetic tests on the Internet and pro-
posed that any initiatives linked to these should be pri-
vately funded and not covered as part of the state funded
health care system.
The results of the ranking exercise showed all participants
were agreed on one point: that the current gatekeeper
model of primary care was not going to be able to deliver
the genetic assessment, counselling and possibly testing
that patients would require. However, participants felt
genetic services should remain close to primary care,
either in community settings or co-located and delivered
by practitioners with specialist skills in this area, such as a
general medical or nurse practitioner with a special inter-
est. These models, including the current delivery model,
were ranked higher than innovations based on telephone-
based assessment alone or those located in different con-
tractor professions. No model was a clear favourite among
all three groups.
Discussion
Principal findings
Those general practitioners who accepted the invitation to
hear about genetic developments iand take part in the
nominal group process did not believe current systems
were sufficient to meet anticipated patient demand for
genetic services. Within the group process practitioners
proposed a wide range of different service options,
although no single option emerged as a clear preference
for those participating. Surprisingly no argument was put
forward for genetic assessment and counselling being cen-
tral to family practice, neither was there a voice for the
view that the family doctor should become skilled at
advising patients about predictive genetic testing and be
able to counsel patients about the wider implications of
genetic testing for patients and their family members.
The views emerging from the groups reflected those of
practitioners who are in routine NHS practice and there-
fore may not be considering the wider or future impact of
not undertaking genetic assessment in primary care. Nev-
ertheless, all the preferred models put a high priority on
providing the service in the community, and often co-
located with general practice. Although not directly
addressed in the suggested service models, it was clear that
the general practitioners had an open mind about which
professional group would be best placed to undertake
genetic counselling. Their understanding of the current
secondary care model was that nurses with special train-
ing undertake the assessments.
Strengths and weaknesses
The use of the nominal group process is strength of this
study. It is a recognised means of allowing participants to
give free rein to ideas, without constraint. The only limita-
tion on the process is the knowledge and experience of
those taking part in the group. It was unfortunate that the
sample size was small. On the basis of prior attendance at
postgraduate events similar to this one, 60 participants
had been expected. The small sample size may be
explained by the subject being given a low priority: this
area of practice is not yet seen as having urgency in the
mind of service based general practitioners. Participants
had noted a slight increase demand for genetic advice,
particularly among women concerned about breast or
ovarian cancer, however increased requests for other types
of predictive genetic testing had been experienced. Some
will regard the non-specialist perspective of this work as a
weakness but the study was purposefully designed to
obtain the preferences of service-based general practition-
ers as a 'bottom-up' exercise to identify the delivery mod-
els felt to be appropriate and applicable in the evolving
primary care context.
Results in context
Placed in the context of publications that describe the
expected impact of predictive genetic testing [16,17] there
are few studies in which the effectiveness of different serv-
ice delivery models has been examined. Holloway
reported a study demonstrating the economy of using
postal questionnaires compared to specialist nurse inter-
views as a means of assessing familial breast cancer risk
[12]. Campbell reported a cluster randomised trial of a GP
based genetic clinic, versus the normal practice of referral
to a regional service and showed a larger increase in refer-
ral rates when clinics were based in primary care and that
patients from the GP clinic had an inappropriate level
interest and expectation of the appropriateness of genetic
testing [10]. Elwyn reported reactions to a nurse-led triage
system [18]. These studies did not consider other possible
service delivery models. The work reported in this study
provides a wider canvas of possible models and novelBMC Family Practice 2005, 6:14 http://www.biomedcentral.com/1471-2296/6/14
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approaches. Genetic counselling and testing services need
to combine accurate, comprehensive genetic risk assess-
ment with methods that can be both local and sensitive to
family contexts. It may be possible for general practice in
the UK to develop expertise in genetic assessment, using
the possibility of contracting for enhanced services.
Conclusion
As a result of developments in genetics, there are increas-
ing demands being made on primary care and genetic
services to address patient concerns and manage requests
for genetic advice, risk assessment and testing. Innova-
tions in the ways services could be delivered have started
to appear but there is a lack of discussion and planning
about how the NHS intends to deal with the impact of the
new genetics. General practitioners agree that the current
referral processes and structures are unlikely to meet antic-
ipated needs, but they do not have agreement about how
services could be re-designed to meet anticipated demand.
The practitioners suggested a range of potential service
delivery models: the common thread among those which
were ranked highest was that the service should be located
close to communicates and work in close liaison, or
embedded in, primary care provision. There is a need for
a wider debate about how healthcare systems address how
individual concerns about genetic risk are counselled and
managed, especially given the likely commercial market-
ing of genetic tests. This study demonstrates that there is
no obvious preferred solution to the problem of designing
a service or system to provide genetic advice and assess-
ment to an increasing number of patients and an implicit
sense of scepticism about the likely impact of the new
genetics, echoing other commentators [19]. It was also
unclear how clinicians were expected to integrate genetic
information about individuals and their relatives across
an integrated electronic patient record shared between
healthcare organisations – an area where concerns about
data security and confidentiality abound. General practi-
tioners are willing to suggest a range of models but there
is no clear preference. From the groups, it was presumed
that as a routine service, primary care practitioners would
not undertake detailed genetic assessments but were open
to the concept of a specialist in this area operating in a pri-
mary care arena. The practitioners did not differentiate
between genetic concerns that were likely to be more fre-
quent and therefore might be considered to become part
of the primary care service, such as the stratification of
women with a family history of breast or ovarian cancer
into risk categories and then referring those who were cal-
culated to be above population risk. Whether the aggre-
gated views of this selected sample would find resonance
among other stakeholders needs to be explored.
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